Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Pharm Des ; 18(27): 4215-22, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22632606

RESUMO

Activated protein C (APC), a protease with anticoagulant and cytoprotective activities, protects neurons and cerebrovascular endothelium from ischemic injury. A recombinant APC, drotrecogin alfa (activated) (DrotAA) (Xigris®), was approved by the Food and Drug Administration for the treatment of sepsis; however, serious bleeding was a dose-limiting side effect. A modified APC, containing 405 amino acid residues, 3K3A-APC, was designed to possess significantly reduced anticoagulant activity ( < 10 %) while maintaining full cytoprotective properties. The preclinical safety assessment of 3K3A-APC was conducted to support initiation of ischemic stroke clinical trials.The safety and toxicokinetics of 3K3A-APC were studied in CD-1 mice and cynomolgus monkeys. Multiple-dose (14-day), intravenous GLP toxicology assessed toxicity, histopathology, immunogenicity, and toxicokinetics.Dose-related increases in plasma total 3K3A-APC were observed in mice and monkeys with no evidence of accumulation over 14 days. The elimination T(1/2) in monkeys was 1 hour. 3K3A-APC was well tolerated in mice and monkeys, and no signs of 3K3A-APC toxicity were identified in mice or monkeys at any time. Additionally,wild-type APC (DrotAA) was studied to obtain comparative anticoagulant data using clotting assays. Anticoagulant activity of 3K3A-APC was observed in monkeys at doses of 1 and 5 mg/kg/day .In contrast, DrotAA showed prolongation of clotting assays in monkeys at doses 1/10(th) of those showing effects with 3K3A-APC. Based upon the anticoagulant profiles, the risk for APC-induced bleeding in clinical trials of 3K3A-APC is greatly reduced relative to wild type APC which makes this new drug a feasible therapy for ischemic stroke patients.


Assuntos
Anticoagulantes/administração & dosagem , Proteína C/administração & dosagem , Sequência de Aminoácidos , Animais , Anticoagulantes/farmacocinética , Anticoagulantes/toxicidade , Coagulação Sanguínea/efeitos dos fármacos , Testes de Coagulação Sanguínea , Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/fisiopatologia , Relação Dose-Resposta a Droga , Estudos de Viabilidade , Feminino , Meia-Vida , Macaca fascicularis , Masculino , Camundongos , Camundongos Endogâmicos ICR , Proteína C/farmacologia , Proteína C/toxicidade , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/toxicidade , Especificidade da Espécie , Acidente Vascular Cerebral/tratamento farmacológico , Acidente Vascular Cerebral/fisiopatologia
2.
Graefes Arch Clin Exp Ophthalmol ; 249(6): 833-8, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21107855

RESUMO

PURPOSE: Although activated protein C (APC) is effective in preventing the death of retinal neurons in ischemic retinopathy, it is not known at what concentrations it becomes retinotoxic. The purpose of this study was to determine the concentrations of intravitreal APC that are safe and those that are toxic for the retina, using rabbit eyes. METHODS: The left eyes of 12 rabbits received an intravitreal injection of 1.5 to 150 µg of APC in 0.1 ml of saline. The fellow eyes were treated with an intravitreal injection of the same amount of saline. Slit-lamp examination, fundus examination, fluorescein angiography (FA), and electroretinograms (ERGs) were performed before and at different times after the injection. The eyes were enucleated at 6 months after the injection and examined histologically. RESULTS: The clinical and histological differences between the control eyes and the eyes that had APC injections up to 15 µg were not significant. Localized retinal edema was observed in two of three eyes with 150 µg of APC immediately after the injection. In these two eyes, chorioretinal atrophy was observed in the area of the retinal edema at 6 months, which corresponded with a hyperfluorescent area in the FA images and focal retinal degeneration histologically. No significant changes were detected in the full-field ERGs in the eyes treated even with 150 µg of APC throughout the observation period. CONCLUSION: Our results show that an intravitreal injection of APC at a dose ≤15 µg is safe, but 150 µg of APC can be toxic to the retina.


Assuntos
Proteína C/toxicidade , Retina/efeitos dos fármacos , Corpo Vítreo/efeitos dos fármacos , Animais , Eletrorretinografia/efeitos dos fármacos , Angiofluoresceinografia , Injeções Intravítreas , Oftalmoscopia , Coelhos , Proteínas Recombinantes/toxicidade , Retina/fisiologia
3.
Cardiovasc Drugs Ther ; 20(2): 113-21, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16761191

RESUMO

PURPOSE: In reperfusion injury activation of coagulation and inflammation contribute to organ dysfunction. Activated protein C (APC) exhibits anticoagulant and anti-inflammatory properties in models of reperfusion injury. We hypothesized that APC could be cardioprotective after ischemia and cardiopulmonary bypass (CPB). METHODS: 20 pigs, undergoing 120 min of CPB and aortic cross-clamping, were randomized to receive 1 mg of human APC or placebo to the last cardioplegic solution given 15 min before declamping to the systemic circulation. After aortic declamping the heart was supported by continuing CPB for 30 min followed by 30 min surveillance. Thrombin-antithrombin complexes, neutrophil L-selectin expression in blood and myeloperoxidase activity (MPO) of myocardial biopsies were measured. RESULTS: There was no indication of APC-induced increased bleeding. Thrombin levels were significantly lower in the APC group than in the placebo group and so were the rates of thrombin formation during the first 3 min of reperfusion and between 10 and 30 min after declamping. There were no differences in MPO or in the proportion of L-selectin (+) to L-selectin (-) neutrophils between groups. Significant systolic hypotension in the APC group was observed at 30 and 45 min compared with the placebo group which associated with the increased mortality observed in the APC group (p = 0.019). CONCLUSIONS: Human APC in cardioplegic solution during CPB in pigs, decreased reperfusion induced thrombin formation with no associated bleeding. No anti-inflammatory effects of human APC were seen. However, in this setting, APC caused hemodynamic deterioration. The observed phenomenon could be explained by systolic hypotension potentially produced by the release of vasoactive substances generated by the APC activation of PARs in the endothelium.


Assuntos
Soluções Cardioplégicas/toxicidade , Vasos Coronários/efeitos dos fármacos , Proteína C/toxicidade , Traumatismo por Reperfusão/fisiopatologia , Animais , Antitrombina III/antagonistas & inibidores , Antitrombina III/metabolismo , Soluções Cardioplégicas/uso terapêutico , Ponte Cardiopulmonar/métodos , Vasos Coronários/metabolismo , Vasos Coronários/fisiopatologia , Modelos Animais de Doenças , Ventrículos do Coração/efeitos dos fármacos , Ventrículos do Coração/metabolismo , Ventrículos do Coração/fisiopatologia , Hemodinâmica/efeitos dos fármacos , Humanos , Hipotensão/induzido quimicamente , Hipotensão/fisiopatologia , Selectina L/metabolismo , Miocárdio/metabolismo , Miocárdio/patologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Neutrófilos/patologia , Peptídeo Hidrolases/metabolismo , Peroxidase/metabolismo , Proteína C/metabolismo , Proteína C/uso terapêutico , Distribuição Aleatória , Receptores Ativados por Proteinase/metabolismo , Suínos , Fatores de Tempo
4.
Crit Care ; 10(2): R47, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16542507

RESUMO

INTRODUCTION: The aim of this study was to investigate the effects of activated protein C (aPC) on vascular function, endothelial injury, and haemostasis in a rabbit endotoxin-induced shock model. METHOD: This study included 22 male New Zealand rabbits weighing 2.5 to 3 kg each. In vitro vascular reactivity, endothelium CD31-PECAM1 immunohistochemistry, plasma coagulation factors and monocyte tissue factor (TF) expression were performed 5 days (D5) after onset of endotoxic shock (initiated by 0.5 mg/kg intravenous bolus of Escherichia coli lipopolysaccharide (LPS)) with or without treatment with aPC injected as an intravenous 2 mg/kg bolus 1 hour after LPS (LPS+aPC group and LPS group, respectively). RESULTS: LPS decreased the sensitivity to phenylephrine (PE) in aortic rings without endothelium (E-) when compared to E- rings from the control group (p < 0.05). This was abolished by NG-nitro-L-arginine methyl ester and not observed in E- rings from aPC-treated rabbits. Although aPC failed to decrease monocyte TF expression in endotoxinic animals at D5, aPC treatment restored the endothelium-dependent sensitivity in response to PE (2.0 +/- 0.2 muM in rings with endothelium (E+) versus 1.0 +/- 0.2 microM in E- rings (p < 0.05) in the LPS+aPC group versus 2.4 +/- 0.3 microM in E+ rings versus 2.2 +/- 0.2 microM in E- rings (p value not significant), in the LPS group). Endotoxin-induced de-endothelialisation was reduced by aPC at D5 (28.5 +/- 2.3% in the LPS+aPC group versus 40.4 +/- 2.4% in the LPS group, p < 0.05). CONCLUSION: These data indicate that aPC increased the sensitivity to a vasoconstrictor agent (PE) associated with restoration of endothelial modulation, and protected against endothelial histological injury in endotoxin-induced shock. It failed to inhibit TF expression at D5 after LPS injection.


Assuntos
Endotoxinas/toxicidade , Proteína C/toxicidade , Choque Séptico/sangue , Choque Séptico/fisiopatologia , Vasoconstrição/fisiologia , Animais , Humanos , Masculino , Coelhos
5.
Haemostasis ; 26(4): 203-9, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8872131

RESUMO

The importance of bleeding as a complication of anticoagulant therapy is clearly recognized. We previously reported that amelioration of hemorrhage associated with disseminated intravascular coagulation by the human activated protein C (APC) was greater than that by heparin. In this study, we compared the bleeding complication of intravenously administered APC and heparin in rabbits, and also estimated primary hemostasis. When both anticoagulants were intravenously infused, the bleeding time from a punctured ear vein was prolonged dose-dependently. However, at doses which prolonged the activated partial thromboplastin time nearly equally, the prolongation of bleeding was greater in heparin-administered rabbits. Blood withdrawn from heparin-administered animals showed increases in in vitro bleeding parameters which correlated with the in vivo bleeding time. However, only small changes were observed in the blood withdrawn from APC-administered animals. Both drugs induced either no change or only a slight decrease in the platelet count, hematocrit and fibrinogen content. These observations suggest that APC may be a more useful anticoagulant than heparin since it causes less bleeding tendency.


Assuntos
Anticoagulantes/toxicidade , Testes de Coagulação Sanguínea/instrumentação , Hemorragia/induzido quimicamente , Heparina/toxicidade , Proteína C/toxicidade , Animais , Anticoagulantes/farmacologia , Tempo de Sangramento , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Ativação Enzimática , Fibrinogênio/análise , Hematócrito , Heparina/farmacologia , Humanos , Infusões Intravenosas , Masculino , Tempo de Tromboplastina Parcial , Contagem de Plaquetas/efeitos dos fármacos , Proteína C/metabolismo , Proteína C/farmacologia , Coelhos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...